



## CTD TABLE OF CONTENTS

SECTION	SUB SECTION	CONTENT	PAGE NUMBER
<b>MODULE 1</b>			
1.0		Cover Letter	
1.1		Table of Contents of the application including Module 1	
1.2		<b>Application Information</b>	
	1.2.1	Application Letter	
	1.2.2	Registration Form	
	1.2.3	Certificate of Incorporation	
	1.2.4	Power of Attorney	
	1.2.5	Notarised Declaration of the applicant	
	1.2.6	Power of Attorney /Contract Manufacturing Agreement	
	1.2.7	Certificate of Pharmaceutical Product	
	1.2.8	Certificate of Good Manufacturing Practice	
	1.2.9	Manufacturing Authorisation	
	1.2.10	Evidence of Trademark Registration	
	1.2.11	Superintendent Pharmacist's Annual Licence to Practice	
	1.2.12	Certificate of Registration and Retention of Premises	
	1.2.13	Evidence of Previous Marketing Authorisation (If Applicable)	
	1.2.14	Invitation Letter for GMP Inspection	
	1.2.15	Copy of Certificate of Suitability of the European Pharmacopoeia (where applicable)	
	1.2.16	Letter of Access for APIMF(s) (where applicable)	
	1.2.17	Biowaiver Request in relation to conducting BCS-based bioavailability study	
	1.2.18	Biowaiver request in relation to conducting Additional Strength bioavailability study	
1.3		<b>Product Information</b>	
	1.3.1	Summary of Product Characteristics (SmPC)	
	1.3.2	Labelling (outer & inner labels)	
	1.3.3	Package Insert (also known as patient information PIL)	
1.4		<b>Regional Summaries</b>	
	1.4.1	Bioequivalence Trial Information Form (BTIF) in Word format	
	1.4.2	Quality Information Summary (QIS) in Word format	
1.5		Electronic Review Documents	
1.6		Samples	



## Module 2 – Common technical document (CTD) summaries

2.1	CTD Table of contents (Modules 2-5)	
2.2	CTD Introduction	
2.3	Quality overall summary – product dossier (QOS-PD) in Word format	
2.5	Clinical overview	
2.7	Clinical summary	

## Module 3 – Quality

3.1	<b>Table of contents of module 3</b>	
3.2	<b>Body of data</b>	
3.2.S	<b>Drug Substance</b>	

Sr. No.	Contents	Page Nos.
3.2.S.1	<b>General information</b>	
	3.2.S.1.1 Nomenclature	
	3.2.S.1.2 Structure	
	3.2.S.1.3 General properties	
3.2.S.2	<b>Manufacture</b>	
	3.2.S.2.1 Manufacturer(s)	
	3.2.S.2.2 Description of manufacturing process and process controls	
	3.2.S.2.3 Control of materials	
	3.2.S.2.4 Controls of critical steps and intermediates	
	3.2.S.2.5 Process validation and/or evaluation	
	3.2.S.2.6 Manufacturing process development	
3.2.S.3	<b>Characterisation</b>	
	3.2.S.3.1 Elucidation of structure and other characteristics	
	3.2.S.3.2 Impurities	
3.2.S.4	<b>Control of drug substance</b>	
	3.2.S.4.1 Specification	
	3.2.S.4.2 Analytical procedures	
	3.2.S.4.3 Validation of analytical procedures	
	3.2.S.4.4 Batch analyses	
	3.2.S.4.5 Justification of specification	
3.2.S.5	<b>Reference standards or materials</b>	
3.2.S.6	<b>Container closure system</b>	



<b>3.2.S.7</b>	<b>Stability</b>	
	3.2.S.7.1 Stability summary and conclusion	
	3.2.S.7.2 Post approval stability protocol and stability commitment	
	3.2.S.7.3 Stability data	
<b>3.2.P</b>	<b>Drug product</b>	
3.2.P.1	Description and composition of the drug product	
3.2.P.2	<b>Pharmaceutical development</b>	
3.2.P.3	<b>Manufacture</b>	
	3.2.P.3.1 Manufacturer(s)	
	3.2.P.3.2 Batch formula	
	3.2.P.3.3 Description of manufacturing process and process controls	
	3.2.P.3.4 Controls of critical steps and intermediates	
	3.2.P.3.5 Process validation and/or evaluation	
3.2.P.4	<b>Control of excipients</b>	
	3.2.P.4.1 Specifications	
	3.2.P.4.2 Analytical procedures	
	3.2.P.4.3 Validation of analytical procedures	
	3.2.P.4.4 Justifications of specifications	
	3.2.P.4.5 Excipients of human or animal origin	
	3.2.P.4.6 Novel excipients	
3.2.P.5	<b>Control of drug product</b>	
	3.2.P.5.1 Specification(s)	
	3.2.P.5.2 Analytical procedures	
	3.2.P.5.3 Validation of analytical procedures	
	3.2.P.5.4 Batch analyses	
	3.2.P.5.5 Characterisation of impurities	
	3.2.P.5.6 Justification of specification(s)	
3.2.P.6	<b>Reference standards or materials</b>	
3.2.P.7	<b>Container closure system</b>	
3.2.P.8	<b>Stability</b>	
	3.2.P.8.1 Stability summary and conclusion	
	3.2.P.8.2 Post approval stability protocol and stability commitment	



	3.2.P.8.3 Stability data	
3.2.A	<b>Appendices</b>	
	3.2.A.1 Facilities and equipments	
	3.2.A.2 Adventitious agents' safety evaluation	
	3.2.A.3 Excipients	
3.2.R	<b>Regional information</b>	
	3.2.R.1 Production documentation	
	3.2.R.1.1 Executed production documents	
	3.2.R.1.2 Master production documents	
	3.2.R.2 Analytical procedures and validation information	
	<b>Module 4 Nonclinical study reports</b> — <i>generally not applicable for generic products</i>	
4.1	Table of contents of Module 4	
4.2	Study reports	
4.3	Literature references	
	<b>Module 5 – Clinical study reports</b>	
5.1	Table of content of Module 5	
5.2	Tabular Listing of All Clinical Studies	
5.3	Clinical Study Reports	
	5.3.1 Reports of Biopharmaceutic Studies	
	5.3.1.2 Comparative BA and Bioequivalence (BE) Study Reports	
	5.3.1.3 In vitro-In vivo Correlation Study Reports	
	5.3.1.4 Reports of Bioanalytical and Analytical Methods for Human Studies	
	5.3.7 Case Report Forms and Individual Patient Listings	
	5.4 Literature References	